Concepedia

Andrew R. Branagan

AR

41

Publications

3K

Citations

26

H-Index

2004

Active since

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Massachusetts General Hospital

Brigham and Women's Hospital

University of Maryland, Baltimore

Andrew R. Branagan is an author at Dana-Farber Cancer Institute specializing in medicine, immunology, and immunotherapy.

ORCID

Top concepts

Publications per year

2004–2024

41

Publications

41

Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia

Steven P. Treon, Mark Hansen, Andrew R. Branagan et al. · Journal of Clinical Oncology · 2005 · 255 citations · Full text

Clonal Immunoglobulin against Lysolipids in the Origin of Myeloma

Shiny Nair, Andrew R. Branagan, Jun Liu et al. · New England Journal of Medicine · 2016 · 203 citations · Full text

Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248

Steven P. Treon, Zachary R. Hunter, Jeffrey Matous et al. · Clinical Cancer Research · 2007 · 189 citations

Characterization of familial Waldenström's macroglobulinemia

Steven P. Treon, Zachary R. Hunter, Abha Aggarwal et al. · Annals of Oncology · 2005 · 189 citations

, , +5

Extended rituximab therapy in Waldenström's macroglobulinemia

Steven P. Treon, Christos Emmanouilides, Eva Kimby et al. · Annals of Oncology · 2004 · 180 citations

, , +6

Rows per page

1–5 of 41